You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

Hot Topics in Schizophrenia: Expert Poster Presentations From 2023 Psychiatry Congresses

  • Authors: Alan Breier, MD; Leslie Citrome, MD, MPH; Christoph U. Correll, MD; Deanna L. Kelly, PharmD, BCPP; Jonathan M. Meyer, MD; Jose M. Rubio, MD
  • CME / CE Released: 7/26/2023
  • Valid for credit through: 7/26/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    Nurses - 1.00 ANCC Contact Hour(s) (1 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for psychiatrists, primary care physicians, nurse practitioners, physician assistants, nurses, and other clinicians who treat patients with schizophrenia.

The goal of this activity is for learners to be better able to recognize the clinical impact of recent data from key 2023 psychiatry meetings, including APA 2023.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical data pertaining to currently approved antipsychotic therapies for the management of schizophrenia
    • Clinical data from investigational antipsychotic therapies being studied for the management of schizophrenia


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Alan Breier, MD

    Professor of Psychiatry
    Indiana University School of Medicine
    Indianapolis, Indiana, United States

    Disclosures

    Alan Breier, MD, has the following relevant financial relationships: 
    Consultant or advisor for: Arrivo Sirtsei Pharmaceuticals, Inc.; BioXcel Therapeutics; Karuna Therapeutics; Neumarker Inc.; Perception Neuroscience
    Stock options from: Karuna Therapeutics; Perception Neuroscience
    Owns stock (publicly traded) in: Karuna Therapeutics

  • Leslie Citrome, MD, MPH

    Clinical Professor of Psychiatry and Behavioral Sciences
    New York Medical College
    Valhalla, New York, United States

    Disclosures

    Leslie Citrome, MD, MPH, has the following relevant financial relationships: 
    Consultant or advisor for: AbbVie/Allergan; ACADIA Pharmaceuticals Inc.; Alkermes, Inc.; Angelini Pharma; Astellas; Avanir Pharmaceuticals; Axsome Therapeutics, Inc.; BioXcel Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc.; Cadent Therapeutics; Cerevel Therapeutics; Clinilabs; COMPASS; Eisai, Inc.; Enteris BioPharma; HLS Therapeutics; Idorsia Pharmaceuticals, Ltd.; Impel NeuroPharma, Inc.; INmuneBIO; Intra-Cellular Therapies, Inc.; Janssen; Karuna Therapeutics; Lundbeck, Inc.; Lyndra Therapeutics; Marvin; Medavante-ProPhase; Merck; Mitsubishi Tanabe Pharma Corporation; Neurelis, Inc.; Neurocrine Biosciences, Inc.; Novartis; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceuticals Co., Ltd.; Ovid Therapeutics; Praxis Precision Medicines; Recordati; Relmada Therapeutics, Inc.; Reviva Pharmaceuticals, Inc.; Sage Therapeutics, Inc.; Sunovion Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Teva
    Speaker or member of speakers bureau for: AbbVie/Allergan; ACADIA Pharmaceuticals, Inc.; Alkermes, Inc.; Angelini Pharma; Axsome Therapeutics; BioXcel Therapeutics; Eisai, Inc.; Idorsia Pharmaceuticals, Ltd.; Intra-Cellular Therapies, Inc.; Janssen; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceuticals Col, Ltd.; Recordati; Sage Therapeutics, Inc.; Sunovion Pharamaceuticals, Inc.; Takeda; Teva
    Stock options from: Reviva Pharmaceuticals, Inc.
    Owns stock (publicly traded) in: Bristol Myers Squibb Company; Eli Lilly; Johnson and Johnson; Merck; Pfizer

  • Christoph U. Correll, MD

    Professor of Psychiatry and Molecular Medicine
    Zucker School of Medicine at Hofstra
    Northwell, New York
    Professor of Child and Adolescent Psychiatry
    Charité University Germany
    Berlin, Germany

    Disclosures

    Christoph U. Correll, MD, has the following relevant financial relationships: 
    Consultant or advisor for: AbbVie Inc.; ACADIA Pharmaceuticals Inc.; Alkermes, Inc.; Allergan, Inc.; Angelini Pharma; Aristo Pharma (former); Boehringer Ingelheim Pharmaceuticals, Inc.; Cardio Diagnostics; Cerevel Therapeutics; CNX Therapeutics (former); Compass Pathways; Darnitsa (former); Gedeon Richter; Hikma Pharmaceuticals (former); Holmusk; Intra-Cellular Therapies, Inc.; Janssen/Johnson and Johnson; Karuna Therapeutics; LB Pharma; Lundbeck, Inc.; MedAvante-ProPhase; MedinCell; Merck; Mindpax; Mitsubishi Tanabe Pharma Corporation (former); Mylan Laboratories Inc.; Neurocrine Biosciences, Inc.; Newron Pharmaceuticals SPA (former); Noven Pharmaceuticals, Inc.; Novo Nordisk; Otsuka Pharmaceutical Co., Ltd.; Pharmabrain; PPD Biotech; Recordati; Relmada Therapeutics, Inc.; Reviva Pharmaceuticals Inc.; ROVI; Seqirus; SERVIER (former); SK Life Science; Sunovion Pharmaceuticals Inc.; Sun Pharmaceutical Industries, Ltd. (former); Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company; Teva Pharmaceuticals; Viatris
    Speaker or member of speakers bureau for: AbbVie Inc.; Angelini; Aristo Pharma; Darnitsa; Gedeon Richter; Hikma Pharmaceuticals; Intra-Cellular Therapies, Inc.; Janssen/Johnson and Johnson; Lundbeck, Inc.; Mitsubishi Tanabe Pharma Corporation; Mylan Laboratories Inc.; Otsuka Pharmaceutical Co., Ltd.; Recordati; Seqirus; Sunovion Pharmaceuticals, Inc.; Takeda Pharmaceutical Company; Viatris
    Research funding from: Janssen; Takeda Pharmaceutical Company
    Stock options from: Cardio Diagnostics; LB Pharma; Mindpax; Quantic

  • Deanna L. Kelly, PharmD, BCPP

    MPower Professor of Psychiatry
    State of Maryland Strategic Partnership: MPowering the State
    Acting Director, Maryland Psychiatric Research Center
    University of Maryland School of Medicine
    Baltimore, Maryland, United States

    Disclosures

    Deanna L. Kelly, PharmD, has the following relevant financial relationships: 
    Consultant or advisor for: Alkermes, Inc. (former); Janssen; Sunovion Pharmaceuticals Inc. (former)
    Research funding from: Saladax Biomedical Inc.

  • Jonathan M. Meyer, MD

    Voluntary Clinical Professor
    Department of Psychiatry
    University of California, San Diego
    San Diego, California, United States

    Disclosures

    Jonathan M. Meyer, MD, has the following relevant financial relationships: 
    Consultant or advisor for: Alkermes, Inc.; BioXcel Therapeutics; Cerevel Therapeutics; Intra-Cellular Therapies, Inc.; Karuna Therapeutics; Neurocrine Biosciences, Inc.; Otsuka Pharmaceutical Co., Ltd.; Relmada Therapeutics, Inc.; Sunovion Pharmaceuticals Inc.; Teva Pharmaceutical Industries Ltd. 
    Speaker or member of speakers bureau for: Alkermes, Inc.; Axsome Therapeutics, Inc.; Intra-Cellular Therapies, Inc; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Sunovion Pharmaceuticals Inc.; Teva Pharmaceutical Industries Ltd.

  • Jose M. Rubio, MD

    Assistant Professor of Psychiatry
    Zucker School of Medicine at Hofstra
    Northwell, New York, United States

    Disclosures

    Jose M. Rubio, MD, has the following relevant financial relationships: 
    Consultant or advisor for: Janssen; Karuna Therapeutics; Teva 
    Speaker or member of speakers bureau for: Teva
    Research funding from: Alkermes, Inc. 
    Contracted researcher for: Saladax Therapeutics

Editor

  • Frances McFarland, PhD, MA

    Medical Education Director, Medscape, LLC

    Disclosures

    Frances McFarland, PhD, MA, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.00 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

Hot Topics in Schizophrenia: Expert Poster Presentations From 2023 Psychiatry Congresses

Authors: Alan Breier, MD; Leslie Citrome, MD, MPH; Christoph U. Correll, MD; Deanna L. Kelly, PharmD, BCPP; Jonathan M. Meyer, MD; Jose M. Rubio, MDFaculty and Disclosures

CME / CE Released: 7/26/2023

Valid for credit through: 7/26/2024, 11:59 PM EST

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

  • Print